当前位置： SCI文献检索 > Orthopaedics & Traumatology-Surgery & Research期刊下所有文献 > Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion.

Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion.

Abstract：

INTRODUCTION:Previous studies reported that teriparatide (recombinant human parathyroid hormone) accelerated spinal fusion following posterior lumbar inter-body fusion surgery, and combination therapy using teriparatide and denosumab increased bone marrow density more than teriparatide alone. The purpose of this study is to evaluate the influence of combination therapy with teriparaide and denosumab on spinal fusion after posterior lumbar interbody fusion. MATERIALS AND METHODS:Sixteen osteoporotic patients with lumbar canal stenosis were randomly divided into two treatment groups, a teriparatide group (n=8; 20μg of teriparatide daily alone, administered from a month before surgery to 12 months after surgery) and a combination group (n=8; 20μg of teriparatide administered daily from a month before surgery to 12 months after surgery with 60mg denosumab every 6 months, administered at 2 and 8 months following surgery). All patients underwent posterior lumbar interbody fusion with local bone grafts. At 3, 6, 9, and 12 months following surgery, bone mineral density at the femoral neck was measured, and biochemical markers were obtained for bone turnover for all cases. Clinical findings were quantified using the Japanese Orthopedic Association scores before surgery, and at 6 and 12 months following surgery. Fusion rates were measured using computed tomography images before surgery, and 6 and 12 months following surgery. RESULTS:Alkaline phosphatase in the teriparatide group increased more than in the combination group at 3 months following surgery (p<0.05). Femoral neck BMD increased more in the combination group than in the teriparatide group at 12 months following surgery. The combination group achieved higher fusion rates than the teriparatide group at 6 months following surgery. CONCLUSIONS:Combination therapy with teriparatide and denosumab increased bone mineral density more than teriparatide alone, and accelerated spinal fusion following posterior lumbar interbody fusion.

journal_name

Orthop Traumatol Surg Res

journal_title

Orthopaedics & traumatology, surgery & research : OTSR

authors

Ide M,Yamada K,Kaneko K,Sekiya T,Kanai K,Higashi T,Saito T

doi

10.1016/j.otsr.2018.07.015

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

1043-1048

issue

issn

1877-0568

pii

S1877-0568(18)30243-3

journal_volume

104

pub_type

杂志文章,随机对照试验

在线工具

Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion.